Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Injectable Facility (F-3) at Karkhadi from August 18, 2022 to August 30, 2022. This was a pre-approval inspection for ANDAs filed with the USFDA. The company has already started receiving ANDA approvals manufactured at this facility.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.